Skip to main content
GMABNasdaq

Genmab A/S

Pharmaceutical preparations·Phase 3·Copenhagen, Denmark·CEO: Dr. Jan G.J. van de Winkel Ph.D.
OncologyImmunologyDermatologyNephrologyGastroenterology

GMAB evidence brief

What we can confirm

No verified snapshot fields are available yet.

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

Watch the next source-backed data update.
BioSniper AIPage evidence connected

Prepared research question

What matters most for GMAB—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

BioSniper AI · GMAB

Genmab A/S is an international biotechnology company developing antibody-based therapies for cancer and other serious diseases, with a pipeline centered on late-stage programs epcoritamab, Rina-S, and petosemtamab.

Key risk: High debt burden

8.2/10

BioSniper Score

Based on 2 of 6 signals

Limited data coverage

Market Cap

$20.72B

Cash Runway

Lead Asset

Financial data as of Dec 31, 2025.

Tracking 45 clinical trials · 13 catalysts for Genmab A/S.

AI OverviewAI overview is shown in English only.

Genmab A/S is an international biotechnology company developing antibody-based therapies for cancer and other serious diseases, with a pipeline centered on late-stage programs epcoritamab, Rina-S, and petosemtamab.

  • Cash and equivalents of $1,715.0M as of 2025-12-31 [sec].
  • Shareholders' equity of $5,847.0M and total debt of $5,599.0M as of 2025-12-31 [sec].
  • R&D expenses were $459M for Q2 2026, up 26% from Q2 2025, driven by clinical development costs for petosemtamab and Rina-S [sec · filed 2026-08-06].
  • Total liabilities decreased to $6,558M as of June 30, 2026 from $7,026M at year-end 2025 [sec · filed 2026-08-06].
  • Portfolio includes proprietary antibody platforms: DuoBody, HexaBody, DuoHexaBody, and HexElect [sec · filed 2026-02-17].

What works

  • Genmab has multiple late-stage programs (epcoritamab, Rina-S, petosemtamab) advancing through Phase 3 trials, with several topline readouts expected between 2028 and 2029 [sec · filed 2026-02-17].
  • The company has built commercialization capabilities in the US, Japan, and the EU for products like Tivdak and EPKINLY [sec · filed 2026-02-17].
  • Proprietary antibody platforms (DuoBody, HexaBody, etc.) provide a foundation for creating novel bispecific and enhanced-potency antibodies [sec · filed 2026-02-17].

What to weigh

  • Genmab carries significant debt of $5,599.0M as of 2025-12-31, nearly matching shareholders' equity [sec].
  • R&D expenses are rising rapidly (26% increase in Q2 2026), and the company expects further increases from the Merus acquisition, pressuring near-term profitability [sec · filed 2026-08-06].
  • Many product candidates are in early stages and face uncertain, costly clinical development; failure in one trial could harm the entire pipeline [sec · filed 2026-02-17].
  • The company is subject to extensive regulation and commercialization risks, including pricing limitations and competition [sec · filed 2026-02-17].

From the filings

Quoted directly from source documents.

  • Genmab's pipeline focuses on epcoritamab, Rina-S, and petosemtamab.

    Our current priorities are the commercial or late-stage programs epcoritamab, Rina-S and pet

    SEC filings · February 17, 2026

  • R&D expenses increased 26% in Q2 2026 due to clinical development costs.

    Research and development expenses were $459 million for the second quarter of 2026 compared to $364 million for the second quarter of 2025, an increase of $95 million, or 26%.

    SEC filings · August 6, 2026

  • Genmab has proprietary antibody platforms.

    Our portfolio includes multiple proprietary antibody technology platforms: our DuoBody platform, which can be used for the creation and development of bispecific antibodies; our HexaBody platform, which can be used to increase the potential potency of antibodies through hexamerization;

    SEC filings · February 17, 2026

  • Total liabilities decreased to $6,558M as of June 30, 2026.

    As of June 30, 2026, total liabilities were $6,558 million compared to $7,026 million on December 31, 2025.

    SEC filings · August 6, 2026

Catalyst timeline

  • 2028-03-01 · Phase3_Topline · epcoritamab — Phase 3 Topline: A Phase 3, Multicenter, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared to RiFirst topline readout for epcoritamab in combination therapy; results will inform its potential in earlier treatment lines.
  • 2028-04-01 · Phase3_Topline · epcoritamab — Phase 3 Topline: A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in RelaSecond epcoritamab topline readout comparing monotherapy to chemotherapy in relapsed/refractory setting.
  • 2028-05-23 · Phase3_Topline · rinatabart — Phase 3 Topline: A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of InvestigFirst topline readout for Rina-S, an antibody-drug conjugate, in a head-to-head study against investigator's choice.
  • 2028-06-14 · Phase3_Topline · epcoritamab — Phase 3 Topline: A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in RelaAdditional epcoritamab topline readout in a different relapsed/refractory population.
  • 2028-09-30 · Phase3_Topline · acasunlimab — Phase 3 Topline: A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With PeFirst topline readout for acasunlimab, a bispecific antibody, in combination with pembrolizumab.
  • 2028-12-01 · Phase3_Topline · rinatabart — Phase 3 Topline: A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of InvestigSecond topline readout for Rina-S in a different indication.
  • 2029-11-01 · Phase3_Topline · rinatabart — Phase 3 Topline: A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of InvestigThird topline readout for Rina-S, potentially in a later-line setting.
  • 2029-12-01 · Phase3_Topline · rituximab — Phase 3 Topline: A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With RituxEpcoritamab combination study with rituximab topline readout.
Risks & what to watch (4)

Key risks

  • High debt burdenTotal debt of $5,599.0M as of 2025-12-31, nearly equal to shareholders' equity [sec].
  • Rising R&D costsR&D expenses increased 26% in Q2 2026, with further increases expected from Merus acquisition [sec · filed 2026-08-06].
  • Clinical development uncertaintyMany candidates are early-stage; failure in one trial could harm the entire pipeline [sec · filed 2026-02-17].
  • Regulatory and commercialization risksSubject to extensive regulation, pricing limitations, and competition [sec · filed 2026-02-17].

What to watch

  • Phase 3 topline results for epcoritamab in multiple indications starting March 2028 [catalyst_timeline].
  • Phase 3 topline results for rinatabart sesutecan (Rina-S) starting May 2028 [catalyst_timeline].
  • Phase 3 topline results for acasunlimab in September 2028 [catalyst_timeline].
  • Integration and development costs from the Merus acquisition, which are expected to increase R&D and SG&A expenses [sec · filed 2026-02-17].

Sources: SEC filings · Generated August 29, 2026 · How we verify sources →

Run Genmab A/S through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available Genmab A/S facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Evidence & data

Score breakdownBased on 2 of 6 signals · derived from public data

No clinical pipeline tracked — this score reflects financial & catalyst signals only.

Cash RunwayN/A

Cash runway data unavailable

Financial Health6.4

D/E 1.20

Pipeline MaturityN/A

No tracked pipeline phase

Pipeline BreadthN/A

No tracked pipeline candidates

Catalyst Momentum10.0

13 upcoming, next in ~549d

Insider SignalN/A

No insider transactions in the last 180 days

Catalysts

Regulatory

Financials

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

270

Total value held

$1.60B

HolderSharesValue
alliancebernstein l.p.9,557,149$294.4M
arrowstreet capital, limited partnership4,975,324$133.5M
blackrock, inc.4,536,565$121.7M
renaissance technologies llc4,414,550$118.4M
deep track capital, lp3,663,250$98.3M
deerfield management company, l.p.2,462,000$66.1M
first trust advisors lp2,461,342$66.0M
two sigma investments, lp2,339,432$62.8M
morgan stanley2,184,701$58.6M
federated hermes, inc.1,251,590$33.6M

Showing top 10 of 270 institutional holders of Genmab A/S. Open the full 13F history after sign-in.

Short Interest

as of Apr 19, 2026
% of float
1.4%
Days to cover
5.3
Shares short
8,576,449
Daily short volume
-

Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →

GMAB short interest

Governance

Frequently asked questions

What is the AI investment thesis for Genmab A/S?

Genmab A/S is an international biotechnology company developing antibody-based therapies for cancer and other serious diseases, with a pipeline centered on late-stage programs epcoritamab, Rina-S, and petosemtamab.

What is Genmab A/S's next catalyst?

Genmab A/S's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Multicenter, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared to Ri" — expected March 1, 2028.

Who is the CEO of Genmab A/S?

Dr. Jan G.J. van de Winkel Ph.D. is the chief executive officer of Genmab A/S (GMAB).

Where is Genmab A/S headquartered?

Genmab A/S (GMAB) is headquartered in Copenhagen, Denmark.

What therapeutic areas does Genmab A/S focus on?

Genmab A/S develops therapies across Oncology, Immunology, Dermatology, Nephrology, Gastroenterology.

925 companies232,681 SEC filings21,417 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.